Search

Your search keyword '"Ysebaert, Loic"' showing total 718 results
Start Over Author "Ysebaert, Loic"
718 results on '"Ysebaert, Loic"'

201. A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Author

Baran-Marszak, Fanny, Vidal, Valerie, Hormi, Myriam, Eclache, Virginie, Veronese, Lauren, Tournilhac, Olivier, Davi, Frederic, Nguyen-Khac, Florence, Leblond, Veronique, Delabesse, Eric, Ysebaert, Loic, Bidet, Audrey, Dilhuydy, Marie-Sarah, Poulain, Stephanie, Herbaux, Charles, Estienne, Marie-Helene, Dartigeas, Caroline, Pastoret, Cedric, de Guibert, Sophie, Giraudier, Stephane, Dupuis, Jehan, Cornillet-Lefebvre, Pascale, Quinquenel, Anne, Laibe, Sophy, Aurran, Thérèse, Naguib, Dina, Troussard, Xavier, Sujobert, Pierre, Michallet, Anne-Sophie, Thieblemont, Catherine, Letestu, Remi, Lazarian, Gregory, Levy, Vincent, Soussi, Thierry, Raynaud, Sophie, and Cymbalista, Florence

Published
2017
Full Text
View/download PDF

204. Phase II, Multicenter Trial, Exploring “Chemo-Sparing” Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Induction Phase of the Icll-07 Filo Study

Author

Michallet, Anne-Sophie, Dilhuydy, Marie-Sarah, Subtil, Fabien, Rouille, Valérie, Mahe, Beatrice, Laribi, Kamel, Villemagne, Bruno, Salles, Gilles Andre, Tournilhac, Olivier, Delmer, Alain Jacques, Portois, Christelle, Pegourie, Brigitte, Leblond, Veronique, Tomowiak, Cecile, de Guibert, Sophie, Orsini, Frederique, Banos, Anne, Carassou, Philippe, Cartron, Guillaume, Fornecker, Luc Mathieu, Ysebaert, Loic, Dartigeas, Caroline, Truchan, Margot, Aurran, Thérèse, Cymbalista, Florence, Leprêtre, Stéphane, Levy, Vincent, Nguyen Khac, Florence, Le Garff-Tavernier, Magali, Aanaei, Carmen, Ticchioni, Michel, Letestu, Remi, and Feugier, Pierre

Published
2017
Full Text
View/download PDF

205. Systematic review of rash in cancer patients receiving ibrutinib and idelalisib

Author

Maria Lia Palomba, Mario E. Lacouture, Vincent Sibaud, Zhe Hou, Viswanath Reddy Belum, and Ysebaert Loic

Subjects
Cancer Research, biology, business.industry, Cancer, Macroglobulinemia, medicine.disease, Rash, chemistry.chemical_compound, Oncology, chemistry, immune system diseases, hemic and lymphatic diseases, Ibrutinib, biology.protein, medicine, Cancer research, Bruton's tyrosine kinase, Mantle cell lymphoma, medicine.symptom, Refractory Chronic Lymphocytic Leukemia, Idelalisib, business, neoplasms
Abstract

e12655 Background: Ibrutinib is a BTK inhibitor approved for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenstrom’s macroglobulinemia....

Published
2015
Full Text
View/download PDF

207. Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing

Author

Robbe, Pauline, primary, Guièze, Romain, additional, Clifford, Ruth M, additional, de Guibert, Sophie, additional, Timbs, Adele, additional, Dilhuydy, Marie-Sarah, additional, Cabes, Maite, additional, Ysebaert, Loic, additional, Burns, Adam, additional, Nguyen-Khac, Florence, additional, Davi, Frederic, additional, Veronese, Lauren, additional, Combes, Patricia, additional, Le Garff-Tavernier, Magali, additional, Leblond, Veronique, additional, Merle-Béral, Hélène, additional, Alsolami, Reem, additional, Weller, Susanne, additional, Hamblin, Angela, additional, Mason, Joanne, additional, Pettitt, Andrew R, additional, Hillmen, Peter, additional, Taylor, Jenny, additional, Knight, Samantha JL, additional, Schuh, Anna, additional, and Tournilhac, Olivier, additional

Published
2014
Full Text
View/download PDF

208. Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial

Author

de Guibert, Sophie, primary, Dilhuydy, Marie-Sarah, additional, Ysebaert, Loic, additional, Sanhès, Laurence, additional, Choquet, Sylvain, additional, Aurran-Schleinitz, Therese, additional, Guieze, Romain, additional, Mahe, Beatrice, additional, Daguindau, Nicolas, additional, Araujo, Carla, additional, Saad, Hussam, additional, Ferrant, Emmanuelle, additional, Cazin, Bruno, additional, Feugier, Pierre, additional, Dreyfus, Brigitte, additional, Alain, Delmer, additional, Lepretre, Stéphane, additional, Le Garff-Tavernier, Magali, additional, Lauren, Véronese, additional, Schuh, Anna, additional, Pereira, Bruno, additional, Leblond, Veronique, additional, and Tournilhac, Olivier, additional

Published
2014
Full Text
View/download PDF

212. Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-Emptive Treatment: An EU-MCL and Lysa Study

Author

Cheminant, Morgane, primary, Schmit, Stephanie, additional, Touzart, Aurore, additional, Derrieux, Coralie, additional, Delfau-Larue, Marie-Hélène, additional, Thieblemont, Catherine, additional, Ribrag, Vincent, additional, Ysebaert, Loic, additional, Jardin, Fabrice, additional, Cheze, Stephane, additional, Lefrère, Francois, additional, Delarue, Richard, additional, Pott, Christiane, additional, Hoster, Eva, additional, Dreyling, Martin, additional, Asnafi, Vahid, additional, Hermine, Olivier, additional, and Macintyre, Elizabeth, additional

Published
2014
Full Text
View/download PDF

213. Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group

Author

Gressin, Remy, primary, Callanan, Mary, additional, Daguindau, Nicolas, additional, Tempescul, Adrian, additional, Carras, Sylvain, additional, Moles, Marie Pierre, additional, Cartron, Guillaume, additional, Houot, Roch, additional, Dartigeas, Caroline, additional, Pignon, Jean Michel, additional, Corm, Selim, additional, Banos, Anne, additional, Mounier, Christiane, additional, Dupuis, Jehan, additional, Macro, Margareth, additional, Fleury, Joel, additional, Jardin, Fabrice, additional, Karlin, Lionel, additional, Feugier, Pierre, additional, Fornecker, Luc Matthieu, additional, Chabrot, Cecile, additional, Dorvaux, Veronique, additional, Bouabdallah, Krimo, additional, Amorin, Sandy, additional, Garidi, Reda, additional, Voillat, Laurent, additional, Joly, Bertrand, additional, Le Dû, Katell, additional, Morineau, Nadine, additional, Zerazhi, Hacene, additional, Fontan, Jean, additional, Arkam, Yazid, additional, Alexis, Magda, additional, Delwail, Vincent, additional, Vilque, Jean Pierre, additional, Ysebaert, Loic, additional, Le Gouill, Steven, additional, and Damaj, Ghandi, additional

Published
2014
Full Text
View/download PDF

214. Concomitant Systemic and Neuro-Meningeal Non-Hodgkin’s Lymphoma: The Role of Consolidation with Intensive Chemotherapy and Autologous Stem Cell Transplantation. a Retrospective Study of 65 Cases

Author

Damaj, Gandhi, primary, Ivanoff, Sarah, additional, Coso, Diane, additional, Ysebaert, Loic, additional, Choquet, Sylvain, additional, Houillier, Caroline, additional, Abarah, Wajed, additional, Marjanovic, Zora, additional, Garidi, Reda, additional, Diouf, Momar, additional, Gac, anne Claire, additional, Dupuis, Jehan, additional, Morschhauseur, Franck, additional, Ghesquieres, Herve, additional, and Soussain, Carole, additional

Published
2014
Full Text
View/download PDF

217. Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).

Author

Casasnovas, Rene-Olivier, primary, Ysebaert, Loic, additional, Thieblemont, Catherine, additional, Coiffier, Bertrand, additional, Bologna, Serge, additional, Lepeu, Gerard, additional, Delmer, Alain, additional, Plantier, Isabelle, additional, Gabarre, Jean, additional, Andre, Marc, additional, Senecal, Delphine, additional, Fruchart, Christophe, additional, Meignan, Michel, additional, Berriolo-Riedinger, Alina, additional, Bardet, Stephane, additional, Molina, Thierry Jo, additional, Jais, Jean-Philippe, additional, Haioun, Corinne, additional, Tilly, Herve, additional, and Morschhauser, Franck, additional

Published
2014
Full Text
View/download PDF

218. Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia

Author

Guidez, Stephanie, Labreuche, Julien, Drumez, Elodie, Ysebaert, Loic, Bakala, Jana, Delette, Caroline, Hivert, Bénédicte, Protin, Caroline, Declercq, Hervé, Verlay, Mélanie, Marolleau, Jean Pierre, Duhamel, Alain, and Morel, Pierre

Abstract

Few reports assess prognosis during follow-up of patients with symptomatic Waldenström macroglobulinemia (WM). In 121 WM patients treated between 1993 and 2016, we analyzed the prognostic role during the clinical course of the initial International Prognostic Scoring System for WM (IPSSWM). Then, we assessed onset of response, progression, and second treatment initiation coded as time-dependent covariates. High-risk IPSSWM was an adverse prognostic factor for survival after first treatment initiation (SAFTI). Nevertheless, the corresponding Dxy concordance index obtained in multiple landmark analyses decreased from 0.24 to 0.08 during the first 6 years, in accordance with a departure from the proportional hazard assumption. By contrast with onset of response (whatever its level), onset of progression and initiation of second-line treatment retained prognostic value for SAFTI (P= .02 and P= .006, respectively). These findings were confirmed in cause-specific Cox models for deaths related to WM, but not for unrelated deaths. Time to progression after first-line treatment and time to initiation of second-line treatment had no prognostic value for survival after these 2 events. These results were confirmed in an independent series of 119 patients homogeneously treated with chemoimmunotherapy. Finally, after second-line and third-line treatment, onset of progression had significant prognostic value for subsequent risk of related death only. Thus, taking initial IPSSWM and delayed response to treatment into account, only onset of progression and second treatment initiation provided additional prognostic information for SAFTI. Therefore, progression-free survival or time to next treatment may be satisfactory surrogate end points of SAFTI in WM.

Published
2018
Full Text
View/download PDF

221. Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Author

Guieze, Romain, Ysebaert, Loic, Roos-Weil, Damien, Fornecker, Luc-Matthieu, Ferrant, Emmanuelle, Molina, Lysiane, Aurran-Schleinitz, Thérèse, Clavert, Aline, de Guibert, Sophie, Michallet, Anne-Sophie, Saad, Alain, Drenou, Bernard, Quittet, Philippe, Hivert, Benedicte, Laribi, Kamel, Gay, Julie, Broséus, Julien, Rouille, Valérie, Schwartz, David, Pereira, Bruno, Delmer, Alain, and Feugier, Pierre

Published
2022
Full Text
View/download PDF

224. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

Author

Cuccuini, Wendy, Briere, Josette, Mounier, Nicolas, Voelker, Hans-Ullrich, Rosenwald, Andreas, Sundström, Christer, Cogliatti, Sergio, Hirchaud, Edouard, Ysebaert, Loic, Bron, Dominique, Soulier, Jean, Gaulard, Philippe, Houlgatte, Remi, Gisselbrecht, Christian, Thieblemont, Catherine, Cuccuini, Wendy, Briere, Josette, Mounier, Nicolas, Voelker, Hans-Ullrich, Rosenwald, Andreas, Sundström, Christer, Cogliatti, Sergio, Hirchaud, Edouard, Ysebaert, Loic, Bron, Dominique, Soulier, Jean, Gaulard, Philippe, Houlgatte, Remi, Gisselbrecht, Christian, and Thieblemont, Catherine

Abstract

Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC rearrangement in patients with relapsed/refractory DLBCL prospectively treated by R-ICE or R-DHAP followed by highdose therapy and autologous stem cell transplantation. Twenty-eight (17%) of the 161 patients analyzed presented a MYC+ rearrangement, targeted as either simple hit (25%) or complex hits (n = 75%) including MYC/BCL2, MYC/BCL6, and MYC/BCL2/BCL6. Results were statistically highly concordant in matched primary and relapsed biopsies (n = 45). Compared to the MYC+ DLBCL patients, the MYC+ DLBCL patients presented with a more elevated lactico-deshydrogenase level (P = .0006) and a more advanced age adjusted international prognostic index (P = .0039). The 4-year PFS and OS were significantly lower in the MYC+ DLBCL patients than those in the MYC- DLBCL patients, with rates of 18% vs 42% (P = .0322), and of 29% vs 62% (P = .0113), respectively. Type of treatment, R-DHAP or R-ICE, had no impact on survivals, with 4-year PFS rates of 17% vs 19% and 4-year OS rates of 26% vs 31%. In conclusion, MYC rearrangement is an early event in DLBCL. MYC+ DLBCL patients have a significant inferior prognosis than MYC- DLBCL patients. Their outcome was not influenced by the proposed salvage therapy.

Published
2012
Full Text
View/download PDF

225. Collaborateurs à la précédente édition

Author

Adès, Lionel, Ajzenberg, Nadine, Andreu, Georges, Asnafi, Vahid, Avet-Loiseau, Hervé, Bauters, Francis, Beaumont, Carole, Besson, Caroline, Binet, Christian, Boiron, Jean-Michel, Bordessoule, Dominique, Borel-Derlon, Annie, Bridoux, Frank, Cahn, Jean-Yves, Cartron, Guillaume, Casadevall, Nicole, Chavarin, Patricia, Chiaroni, Jacques, Colombat, Philippe, Copin, Marie-Christine, Cymbalista, Florence, Da Costa, Lydie, Delabesse, Éric, Delmer, Alain, Dreyfus, François, Fabrigli, Patrick, Facon, Thierry, Fenaux, Pierre, Fischer, Anne-Marie, Fontenay, Michaela, Gandemer, Virginie, Garban, Frédéric, Garçon, Loïc, Garraud, Olivier, Ghesquières, Hervé, Giraudier, Stéphane, Grosbois, Bernard, Gruel, Yves, Guery, Ève-Anne, Guinier, Marie-Claude, Guyotat, Denis, Helley, Dominique, Hérault, Olivier, Houot, Roch, Hunault, Mathilde, Ifrah, Norbert, Jaccard, Arnaud, James, Chloé, Jolly, Bérangère, Jouet, Jean-Pierre, Kahn, Jean-Emmanuel, Kiladjian, Jean-Jacques, Kosmider, Olivier, de la Chapelle, Thierry Lamy, Leblond, Véronique, Lefrère, Jean-Jacques, Le Gouill, Steven, Legrand, Fanny, Leleu, Xavier, Macchi, Laurent, Marchand, Tony, Milpied, Noël, Morange, Pierre, Morange, Pierre-Emmanuel, Moreau, Philippe, Morschhauser, Franck, Nguyen, Philippe, Nguyen-Khac, Florence, Pirenne, France, Pouplard, Claire, Prin, Lionel, Raynaud, Sophie, Recher, Christian, Robin, Christine, Rouard, Hélène, Rousselot, Philippe, Salles, Gilles, Sarkozy, Clémentine, Schved, Jean-François, Schmidt, Aline, Siguret, Virginie, Socié, Gérard, Susen, Sophie, Tabone, Marie-Dominique, Thieblemont, Catherine, Troussard, Xavier, Ugo, Valérie, Vainchenker, William, Vayne, Caroline, Vey, Norbert, Veyradier, Agnès, Wagner-Ballon, Orianne, Wautier, Jean-Luc, Ysebaert, Loïc, and Zandecki, Marc

Published
2021
Full Text
View/download PDF

226. Collaborateurs à la présente édition

Author

Garçon, Loïc, Delmer, Alain, Maynadié, Marc, Bardet, Valérie, Nguyen-Khac, Florence, Ades, Lionel, Aguilar-Martinez, Patricia, Boyer, Thomas, Broséus, Julien, Cartron, Guillaume, Cayssials, Émilie, Chiaroni, Jacques, Clauser, Sylvain, Cluzeau, Thomas, Cymbalista, Florence, Da Costa, Lydie, D'aveni, Maud, Dumas, Pierre-Yves, Fenneteau, Odile, Feugier, Pierre, Ghesghieres, Hervé, Giraudier, Stéphane, Gruel, Yves, Hérault, Olivier, Herbaux, Charles, Hirsch, Pierre, Hunault, Mathilde, James, Chloé, Lebon, Delphine, Luque-Paz, Damien, Macchi, Laurent, Martin, Mickael, Morange, Pierre, Moreau, Philippe, Pirenne, France, Quinquenel, Anne, Robin, Christine, Rousselot, Philippe, Sujobert, Pierre, Touzeau, Cyrille, Ugo, Valérie, Ballon, Orianne Wagner, and Ysebaert, Loïc

Published
2021
Full Text
View/download PDF

227. The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma : A Bio-CORAL Study

Author

Thieblemont, Catherine, Briere, Josette, Mounier, Nicolas, Voelker, Hans-Ullrich, Cuccuini, Wendy, Hirchaud, Edouard, Rosenwald, Andreas, Jack, Andrew, Sundström, Christer, Cogliatti, Sergio, Trougouboff, Philippe, Boudova, Ludmila, Ysebaert, Loic, Soulier, Jean, Chevalier, Catherine, Bron, Dominique, Schmitz, Norbert, Gaulard, Philippe, Houlgatte, Remi, Gisselbrecht, Christian, Thieblemont, Catherine, Briere, Josette, Mounier, Nicolas, Voelker, Hans-Ullrich, Cuccuini, Wendy, Hirchaud, Edouard, Rosenwald, Andreas, Jack, Andrew, Sundström, Christer, Cogliatti, Sergio, Trougouboff, Philippe, Boudova, Ludmila, Ysebaert, Loic, Soulier, Jean, Chevalier, Catherine, Bron, Dominique, Schmitz, Norbert, Gaulard, Philippe, Houlgatte, Remi, and Gisselbrecht, Christian

Abstract

Purpose: To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBLC), prospectively treated by rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) versus rituximab, ifosfamide, carboplatin, and etoposide and followed by intensive therapy plus autologous stem-cell transplantation on the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) trial. Patients and Methods: Among the 396 patients included on the trial, histologic material was available for a total of 249 patients at diagnosis (n = 189 patients) and/or at relapse (n = 147 patients), which included 87 matched pairs. The patient data were analyzed by immunochemistry for CD10, BCL6, MUM1, FOXP1, and BCL2 expression and by fluorescent in situ hybridization for BCL2, BCL6 and c-MYC breakpoints. The correlation with survival data was performed by using the log-rank test and the Cox model. Results: Characteristics of immunophenotype and chromosomal abnormalities were statistically highly concordant in the matched biopsies. In univariate analysis, the presence of c-MYC gene rearrangement was the only parameter to be significantly correlated with a worse progression-free survival (PFS; P = .02) and a worse overall survival (P = .04). When treatment interaction was tested, the germinal center B (GCB) -like DLBCL that was based on the algorithm by Hans was significantly associated with a better PFS in the R-DHAP arm. In multivariate analysis, independent prognostic relevance was found for the GCB/non-GCB the Hans phenotype interaction treatment (P = .04), prior rituximab exposure (P = .0052), secondary age-adjusted International Prognostic Index (P = .039), and FoxP1 expression (P = .047). Confirmation was obtained by gene expression profiling in a subset of 39 patients. Conclusion: COO remains a major and independent factor in relapsed/refractory DLBCL, with a better response to R-DHAP in GCB-like DLBCL. This needs co

Published
2011
Full Text
View/download PDF

228. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.

Author

UCL - (SLuc) Service d'hématologie, Fitoussi, Olivier, Belhadj, Karim, Mounier, Nicolas, Parrens, Marie, Tilly, Hervé, Salles, Gilles, Feugier, Pierre, Ferme, Christophe, Ysebaert, Loic, Gabarre, Jean, Herbrecht, Raoul, Janvier, Maud, Van Den Neste, Eric, Morschhauser, Franck, Casasnovas, Olivier, Ghesquieres, Hervé, Anglaret, Bruno, Brechignac, Sabine, Haioun, Corinne, Gisselbrecht, Christian, UCL - (SLuc) Service d'hématologie, Fitoussi, Olivier, Belhadj, Karim, Mounier, Nicolas, Parrens, Marie, Tilly, Hervé, Salles, Gilles, Feugier, Pierre, Ferme, Christophe, Ysebaert, Loic, Gabarre, Jean, Herbrecht, Raoul, Janvier, Maud, Van Den Neste, Eric, Morschhauser, Franck, Casasnovas, Olivier, Ghesquieres, Hervé, Anglaret, Bruno, Brechignac, Sabine, Haioun, Corinne, and Gisselbrecht, Christian

Abstract

In high-risk diffuse large B-cell lymphoma patients, treatment with R-ACVBP followed by auto-transplantation results in a 78% 4-year overall survival which should be compared to other approaches.

Published
2011

230. The Ribvd Regimen (Rituximab IV, Bendamustine IV, Velcade SC, Dexamethasone IV) Offers a High Complete Response Rate In Elderly Patients With Untreated Mantle Cell Lymphoma. Preliminary Results Of The Lysa Trial “Lymphome Du Manteau 2010 SA”

Author

Gressin, Remy, primary, Callanan, Mary, additional, Daguindau, Nicolas, additional, Tempescul, Adrian, additional, Carras, Sylvain, additional, Cartron, Guillaume, additional, Schmitt, Anne, additional, Houot, Roch, additional, Dartigeas, Caroline, additional, Pignon, Jean Michel, additional, Corm, Selim, additional, Banos, Anne, additional, Dupuis, Jehan, additional, Mounier, Christiane, additional, Macro, Margareth, additional, Fleury, Joel, additional, Jardin, Fabrice, additional, Kardin, Lionel, additional, Damaj, Gandhi, additional, Feugier, Pierre, additional, Fornacker, luc Matthieu, additional, Chabrot, Cecile molucon, additional, Dorvaux, Veronique, additional, Bouabdallah, Krimo, additional, Amorin, Sandy, additional, Garidi, Reda, additional, Voillat, Laurent, additional, Joly, Bertrand, additional, Solal-Céligny, Philippe, additional, Morineau, Nadine, additional, Moles, Marie Pierre, additional, Zerazhi, Hacene, additional, Fontan, Jean, additional, Arkam, Yazid, additional, Alexis, Magda, additional, Delwail, Vincent, additional, Vilque, Jean Pierre, additional, Ysebaert, Loic, additional, and Le Gouill, Steven, additional

Published
2013
Full Text
View/download PDF

231. P53 Functional Assessment and Correlation With 17p Deletion and/Or TP53 Mutation Status In Chronic Lymphocytic Leukemia (CLL). A Preliminary Report Of The ICLL001 Bomp Trial On Behalf Of The French CLL Intergroup (GCFLLC/MW - GOELAMS)

Author

Le Garff-Tavernier, Magali, primary, Veronese, Lauren, additional, Nguyen-Khac, Florence, additional, Dilhuydy, Marie-Sarah, additional, Combes, Patricia, additional, Leblond, Véronique, additional, Feugier, Pierre, additional, Mahe, Beatrice, additional, Sanhès, Laurence, additional, Delmer, Alain, additional, Ysebaert, Loic, additional, Grelier, Aurore, additional, Truchan-Graczyk, Malgorzata, additional, Dreyfus, Brigitte, additional, Ferrant, Emmanuelle, additional, Leprêtre, Stéphane, additional, Davi, Frederic, additional, Pereira, Bruno, additional, Delepine, Roselyne, additional, Guièze, Romain, additional, Bay, Jacques-Olivier, additional, Merle-Beral, Helene, additional, De Guibert, Sophie, additional, and Tournilhac, Olivier, additional

Published
2013
Full Text
View/download PDF

235. Improved Outcome After Allogeneic Stem-Cell Transplantation (SCT) As Compared to Non-Allogeneic SCT Therapies in Patients with High-Risk Peripheral T-Cell Lymphomas in First Response.

Author

Robles, Margot, primary, Ysebaert, Loic, additional, Vigouroux, Stephane, additional, Huynh, Anne, additional, Parrens, Marie, additional, Bouabdallah, Krimo, additional, Tabrizi, Reza, additional, Leguay, Thibaut, additional, Dilhuydy, Marie-Sarah, additional, Pigneux, Arnaud, additional, Lascaux, Axelle, additional, Duclos, Cedric, additional, Marit, Gerald, additional, and Milpied, Noel, additional

Published
2012
Full Text
View/download PDF

236. Salvage Therapies in Patients with High-Risk Relapse After Fludarabine, Cyclophosphamide, Rituximab (FCR) for Chronic Lymphocytic Leukemia: The French CLL Intergroup Experience

Author

Fornecker, Luc-Matthieu, primary, Aurran-Schleinitz, Therese, additional, Michallet, Anne-Sophie, additional, Cazin, Bruno, additional, Dupuis, Jehan, additional, Guieze, Romain, additional, Dilhuydy, Marie-Sarah, additional, Zini, Jean-Marc, additional, Tomowiak, Cécile, additional, Leprêtre, Stéphane, additional, Cymbalista, Florence, additional, Brion, Annie, additional, Feugier, Pierre, additional, Leblond, Veronique, additional, and Ysebaert, Loic, additional

Published
2012
Full Text
View/download PDF

238. Small Nucleolar RNA Expression Profiling Identifies Potential Prognostic Markers in Peripheral T-Cell Lymphoma.

Author

Ysebaert, Loic, primary, Valleron, Wilfried, additional, Berquet, Laure, additional, Fataccioli, Virginie, additional, Quelen, Cathy, additional, Martin, Antoine, additional, Parrens, Marie, additional, Lamant, Laurence, additional, de Leval, Laurence, additional, Gisselbrecht, Christian, additional, Gaulard, Philippe, additional, and Brousset, Pierre, additional

Published
2012
Full Text
View/download PDF

239. Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma

Author

Valleron, Wilfried, primary, Ysebaert, Loic, additional, Berquet, Laure, additional, Fataccioli, Virginie, additional, Quelen, Cathy, additional, Martin, Antoine, additional, Parrens, Marie, additional, Lamant, Laurence, additional, de Leval, Laurence, additional, Gisselbrecht, Christian, additional, Gaulard, Philippe, additional, and Brousset, Pierre, additional

Published
2012
Full Text
View/download PDF

240. MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

Author

Cuccuini, Wendy, primary, Briere, Josette, additional, Mounier, Nicolas, additional, Voelker, Hans-Ullrich, additional, Rosenwald, Andreas, additional, Sundstrom, Christer, additional, Cogliatti, Sergio, additional, Hirchaud, Edouard, additional, Ysebaert, Loic, additional, Bron, Dominique, additional, Soulier, Jean, additional, Gaulard, Philippe, additional, Houlgatte, Remi, additional, Gisselbrecht, Christian, additional, and Thieblemont, Catherine, additional

Published
2012
Full Text
View/download PDF

241. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

Author

Herbaux, Charles, Gauthier, Jordan, Brice, Pauline, Drumez, Elodie, Ysebaert, Loic, Doyen, Hélène, Fornecker, Luc, Bouabdallah, Krimo, Manson, Guillaume, Ghesquières, Hervé, Tabrizi, Reza, Hermet, Eric, Lazarovici, Julien, Thiebaut-Bertrand, Anne, Chauchet, Adrien, Demarquette, Hélène, Boyle, Eileen, Houot, Roch, Yakoub-Agha, Ibrahim, and Morschhauser, Franck

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) is indicated for patients with relapsed or refractory Hodgkin lymphoma (HL). Although long-term disease control can be achieved, relapse is still frequent. The programmed cell death protein 1 (PD-1) pathway-blocking antibody nivolumab has shown substantial therapeutic activity and an acceptable safety profile in patients with relapsed or refractory HL who did not receive allo-HCT. However, PD-1 blocking strategy can increase the risk of graft-versus-host disease (GVHD) in murine models. We retrospectively assessed the efficacy and toxicity of nivolumab as a single agent in 20 HL patients relapsing after allo-HCT. GVHD occurred in 6 patients (30%) after nivolumab initiation. All 6 patients had prior history of acute GVHD. The patients with nivolumab-induced GVHD were managed by standard treatment for acute GVHD. Two patients died as a result of GVHD, 1 of progressive disease and 1 of complications related to a second allo-HCT. Overall response rate was 95%. At a median follow-up of 370 days, the 1-year progression-free survival rate was 58.2% (95% CI, 33.1%-76.7%) and the overall survival rate was 78.7% (95% CI, 52.4%-91.5%). Among 13 patients still in response, 6 received a single dose of nivolumab and 7 remain on nivolumab. Compared with standard options for this indication, our results show that nivolumab is effective with an acceptable safety profile.

Published
2017
Full Text
View/download PDF

242. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

Author

Jones, Jeffrey A, Robak, Tadeusz, Brown, Jennifer R, Awan, Farrukh T, Badoux, Xavier, Coutre, Steven, Loscertales, Javier, Taylor, Kerry, Vandenberghe, Elisabeth, Wach, Malgorzata, Wagner-Johnston, Nina, Ysebaert, Loic, Dreiling, Lyndah, Dubowy, Ronald, Xing, Guan, Flinn, Ian W, and Owen, Carolyn

Abstract

Idelalisib, a selective inhibitor of PI3Kδ, is approved for the treatment of patients with relapsed chronic lymphocytic leukaemia (CLL) in combination with rituximab. We aimed to assess the efficacy and safety of idelalisib in combination with a second-generation anti-CD20 antibody, ofatumumab, in a similar patient population.

Published
2017
Full Text
View/download PDF

243. Conduire des études épidémiologiques après cancer en France : modalités, difficultés et propositions de solutions. Les enseignements de l’étude SIMONAL sur les toxicités tardives des traitements du lymphome non Hodgkinien

Author

Anthony, Sabine, Hebel, Pierre, Garrel, André, Oliveri, Vanina, Thieblemont, Catherine, Ribrag, Vincent, Tilly, Hervé, Haioun, Corinne, Casasnovas, René-Olivier, Morschhauser, Franck, Feugier, Pierre, Delarue, Richard, Ysebaert, Loic, Sebban, Catherine, Broussais, Florence, Damaj, Gandhi, Nerich, Virginie, Jais, Jean-Philippe, Salles, Gilles, Henry-Amar, Michel, and Mounier, Nicolas

Abstract

Depuis l’introduction des thérapies ciblées, la mortalité du lymphome a diminué mais les effets à long terme ne sont pas bien connus. Cet article décrit la mise en place de l’étude SIMONAL, ayant pour but d’étudier une éventuelle surconsommation de soins 10 ans après traitement du lymphome.

Published
2017
Full Text
View/download PDF

246. PET Evaluation Before Autografting Has a Strong Prognostic Impact in High-Risk, Relapsed Follicular Lymphoma Patients

Author

Ysebaert, Loic, primary, Dupuis, Jehan, additional, Meignan, Michel, additional, Julian, Anne, additional, Recher, Christian, additional, Roussel, Murielle, additional, Oberic, Lucie, additional, Belhadj, Karim, additional, Rigal-Huguet, Francoise, additional, Huynh, Anne, additional, Laurent, Camille, additional, Gaulard, Philippe, additional, Attal, Michel, additional, Haioun, Corinne, additional, and Laurent, Guy, additional

Published
2011
Full Text
View/download PDF

249. The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study

Author

Thieblemont, Catherine, primary, Briere, Josette, additional, Mounier, Nicolas, additional, Voelker, Hans-Ullrich, additional, Cuccuini, Wendy, additional, Hirchaud, Edouard, additional, Rosenwald, Andreas, additional, Jack, Andrew, additional, Sundstrom, Christer, additional, Cogliatti, Sergio, additional, Trougouboff, Philippe, additional, Boudova, Ludmila, additional, Ysebaert, Loic, additional, Soulier, Jean, additional, Chevalier, Catherine, additional, Bron, Dominique, additional, Schmitz, Norbert, additional, Gaulard, Philippe, additional, Houlgatte, Remi, additional, and Gisselbrecht, Christian, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results